Cardiac complications in thalassemia throughout the lifespan: Victories and challenges

Ann N Y Acad Sci. 2023 Dec;1530(1):64-73. doi: 10.1111/nyas.15078. Epub 2023 Oct 30.

Abstract

Thalassemias are among the most common hereditary diseases in the world because heterozygosity offers protection against malarial infection. Affected individuals have variable expression of alpha or beta chains that lead to their unbalanced utilization during hemoglobin formation, oxidative stress, and apoptosis of red cell precursors prior to maturation. Some individuals produce sufficient hemoglobin to survive but suffer the vascular stress imposed by chronic anemia and ineffective erythropoiesis. In other patients, mature red cell formation is insufficient, and chronic transfusions are required-suppressing anemia and ineffective erythropoiesis but at the expense of iron overload. The cardiovascular consequences of thalassemia have changed dramatically over the previous five decades because of evolving treatment practices. This review summarizes this evolution, focusing on complications and management pertinent to modern patient cohorts.

Keywords: arrhythmias; cardiovascular health; chelation; heart failure; iron overload; pulmonary hypertension; thalassemia.

Publication types

  • Review
  • Research Support, U.S. Gov't, P.H.S.
  • Research Support, N.I.H., Extramural

MeSH terms

  • Erythropoiesis
  • Heart
  • Hemoglobins
  • Humans
  • Iron Overload* / complications
  • Iron Overload* / therapy
  • Longevity
  • Thalassemia* / complications
  • Thalassemia* / genetics
  • Thalassemia* / therapy
  • beta-Thalassemia* / complications
  • beta-Thalassemia* / therapy

Substances

  • Hemoglobins